Pennsylvania is currently home to 3306 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT04172532
Recruiting
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Conditions: Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Register for Updates
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598
Recruiting
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia, Pennsylvania
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
NCT06867094
Recruiting
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment p... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/18/2025
Locations: Frontier Clinical Research - Uniontown- Site Number : 8400006, Uniontown, Pennsylvania
Conditions: Colitis Ulcerative
Register for Updates
Utility of the Superior Vena Cava Collapsibility Index (SVC-CI) to Predict Fluid Responsiveness in Patients With Coronary Artery Disease Undergoing Surgical Revascularization
NCT06645327
Recruiting
To investigate the superior vena cava collapsibility index (SVC-CI), measured via transesophageal echocardiography (TEE), as a marker of fluid responsiveness. Two groups will be compared in this study. Groups will be identified by obtaining cardiac output (CO) by standard means using the TEE or pulmonary arterial catheter (PAC). Both of these monitors are considered standard for patient's undergoing coronary artery bypass grafting surgery (CABG) and recording initial CO readings. Based on CO, th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Penn State Hershey Medical Center, Hershey, Pennsylvania
Conditions: Coronary Artery Bypass Grafting Surgery (CABG)
Register for Updates
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045
Recruiting
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Bethlehem, PA, Bethlehem, Pennsylvania
Conditions: Diabetic Macular Edema (DME)
Register for Updates
SIMPLAAFY Clinical Trial
NCT06521463
Recruiting
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Pinnacle Health at Harrisburg Hospital, Harrisburg, Pennsylvania
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733
Recruiting
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main questions it aims to answer are: Does niraparib improve progression-free survival (PFS) compared to TMZ? Does niraparib improve overall survival (OS) compared to TMZ? Participants will be randomly assigned to one of two treatment arms: niraparib or TMZ. * study drug (Niraparib) or * comp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
Register for Updates
RE104 Safety and Efficacy Study in Postpartum Depression
NCT06342310
Recruiting
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/18/2025
Locations: Reunion Investigational Site, West Chester, Pennsylvania
Conditions: Postpartum Depression
Register for Updates
Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity
NCT06340451
Recruiting
This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects with upper extremity spasticity. A total of approximately 132 subjects will be enrolled; 88 subjects will receive treatment with the iovera° system and 44 subjects will receive sham treatment (sham iovera° system treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Moss Rehab Physical Medicine Associates, Elkins Park, Pennsylvania
Conditions: Spasticity, Cerebral or Spinal Condition
Register for Updates
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Local Institution - 0070, Philadelphia, Pennsylvania
Conditions: Multiple Myeloma
Register for Updates
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
NCT06096779
Recruiting
The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Hepatocellular Carcinoma
Register for Updates